1
|
Complement and Immunoglobulin Biology Leading to Clinical Translation. Hematology 2018. [DOI: 10.1016/b978-0-323-35762-3.00024-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
2
|
Abstract
Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibody-coated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood thrombocytopenia. The disease is heterogeneous with regard to its severity and clinical course and is unpredictable in its response to therapy. Although the basic underlying pathophysiology of ITP has been known for more than 50 years, current treatment guidelines are based on expert opinion rather than on evidence because of a lack of high-quality clinical trials and research. The only patients for whom treatment is clearly required are those with severe bleeding and/or extremely low platelet counts (< 10 x 10(9)/L). Treatment of patients with ITP refractory to corticosteroids and splenectomy requires careful evaluation of disease severity, patient characteristics related to risk of bleeding, and adverse effects associated with treatment. Clinical trials with numerous new agents are under way, which we hope will add more effective and targeted strategies to our therapeutic armamentarium. We describe a logical and structured approach to the clinical management of ITP in adults, based on a literature review and our personal experience.
Collapse
MESH Headings
- Adult
- Age Factors
- Alemtuzumab
- Algorithms
- Anti-Inflammatory Agents/therapeutic use
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antibodies, Neoplasm/therapeutic use
- Child
- Danazol/therapeutic use
- Decision Trees
- Disease Progression
- Emergency Treatment/methods
- Estrogen Antagonists/therapeutic use
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Immunosuppressive Agents/therapeutic use
- Incidence
- Male
- Patient Selection
- Platelet Count
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/diagnosis
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Rho(D) Immune Globulin/therapeutic use
- Rituximab
- Splenectomy
Collapse
Affiliation(s)
- Roberto Stasi
- Department of Medical Sciences, "Regina Apostolorum" Hospital, Albano Laziale, Italy.
| | | |
Collapse
|
3
|
Affiliation(s)
- Irina Knezevic-Maramica
- Division of Laboratory and Transfusion Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
| | | |
Collapse
|
4
|
Stephenson MD, Ensom MH. An update on the role of immunotherapy in reproductive failure. Immunol Allergy Clin North Am 2002. [DOI: 10.1016/s0889-8561(02)00004-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Abstract
Technological advancements in the fractionation of plasma in the early 1970s led to the production of immunoglobulin preparations which could be administered intravenously. The ability to deliver larger doses than was possible with intramuscular products was accompanied by clinical studies demonstrating the efficacy of immunoglobulin treatment in a number of autoimmune and inflammatory conditions. This has led to a continuing increase in the usage of this product such that, currently, it is considered to be the driving force for plasma procurement. In recent years, difficulties have been experienced in the supply of this product in various markets. While intravenous immunoglobulins (IVIG) have undoubted clinical superiority over intramuscular products for the majority of indications, their use should be tempered with caution. Early clinical studies revealed that the risk of viral transmission from these products was higher than that of the traditional intramuscular presentation. This has had a profound impact on blood transfusion science as it has provided a major impetus for nucleic acid testing (NAT) for viral agents in blood donations. Perhaps less widely appreciated are the pressures which may be felt in blood services as the traditional drivers for plasma procurement - factor VIII and albumin - become secondary to IVIG. This review discusses the factors affecting the supply and safety of IVIG and the implications of recent global regulatory decisions on the delivery of this product and other therapeutic products derived from human plasma.
Collapse
Affiliation(s)
- A Farrugia
- Blood Products Group, Laboratories Branch, Therapeutic Goods Administration, Australian Department for Health and Aged Care, Woden, ACT. albert
| | | |
Collapse
|
6
|
Abstract
Critical to the proper management of pyoderma gangrenosum are correct diagnosis, identification and treatment of any underlying disorder, and the proper choice of topical and systemic therapy. Many agents are available for the treatment of pyoderma gangrenosum. We review the current therapeutic options, their efficacy and side effects, and we offer some guidelines for their proper selection.
Collapse
Affiliation(s)
- R K Chow
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | | |
Collapse
|
7
|
Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32:140-2. [PMID: 7822511 DOI: 10.1016/0190-9622(95)90218-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- A K Gupta
- Division of Dermatology, Sunnybrook Health Science Center, Toronto, Ontario, Canada
| | | | | |
Collapse
|
8
|
Abstract
Even though IV IgG concentrates are considered to be among the safest products derived from human plasma, some preparations have been associated with the sporadic transmission of NANB hepatitis and, specifically of hepatitis C. The risk of transmission may have decreased markedly for several IgG preparations since the availability of an immunological test to detect the antibodies against HCV in the starting plasma, but it has not been fully eradicated. Thus, in addition to established viral inactivation treatments, such as acid pH incubation, new methods have been (or are being) implemented to further reduce the risk of HCV infection through IV IgG concentrates. Among these methods are the solvent-detergent treatment already shown to be highly effective for the inactivation of HCV and other enveloped viruses in clotting factor concentrates, and nanofiltration for the specific removal of viruses on the basis of their size. Also, chromatographic methods have helped to improve the overall safety of the product not only by removing viruses but also by improving purity and thus favoring a better in vivo tolerance. This paper reviews the reported cases of HCV transmission and the viral validation data for various IV IgG processing steps and current specific viral inactivation methods. An overview of the present safety status of IV IgG concentrates is presented as well as the recent introduction of new promising techniques for the overall improvement of the safety of this plasma derivative.
Collapse
Affiliation(s)
- M Burnouf-Radosevich
- Unité de Recherche et Développement, Laboratoire Français du Fractionnement et des Biotechnologies, Lille
| |
Collapse
|
9
|
Mueller-Eckhardt G. Immunotherapy with intravenous immunoglobulin for prevention of recurrent pregnancy loss: European experience. Am J Reprod Immunol 1994; 32:281-5. [PMID: 7718094 DOI: 10.1111/j.1600-0897.1994.tb01126.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PROBLEM Due to its strong "immunomodulating" effect in several well established disorders, high-dose intravenous immunoglobulins (IVIG) has been proposed as an alternative for immunotherapy with allogeneic leucocytes in patients with unexplained recurrent spontaneous abortion. This paper is intended to provide an overview on the European experience in this field. METHOD Five European pilot studies with a total of 172 patients as well as one controlled double-blind multicenter study including 64 patients were considered. In the latter, 5% human albumin was used as placebo. RESULTS Success rates of the pilot studies varied from 68 to 87%. In the German controlled study, a significant specific effect of IVIG could not be verified. However, success rates for both IVIG and albumin were in the same range as for allogeneic leucocytes. CONCLUSION At present, it is not sufficiently proven that IVIG is an appropriate tool for immunotherapy of recurrent spontaneous abortions. It is suggested that success rates of both IVIG and albumin are due to a placebo effect. However, we cannot exclude that albumin itself provides immunomodulating capacity.
Collapse
|
10
|
Marzusch K, Wiest E, Pfeiffer KH, Grubbe G, Schnaidt M. Antenatal fetal therapy for neonatal allo-immune thrombocytopenia with high dose immunoglobulin. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 1994; 101:1011-3. [PMID: 7999711 DOI: 10.1111/j.1471-0528.1994.tb13052.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- K Marzusch
- Department of Obstetrics and Gynaecology, University of Tuebingen, Germany
| | | | | | | | | |
Collapse
|
11
|
Mant MJ. Chronic idiopathic pure red cell aplasia: successful treatment during pregnancy and durable response to intravenous immunoglobulin. J Intern Med 1994; 236:593-5. [PMID: 7964439 DOI: 10.1111/j.1365-2796.1994.tb00851.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A patient with chronic idiopathic pure red cell hypoplasia responded to intravenous immunoglobulin therapy. No other treatment was administered. During treatment, the patient was taken through two pregnancies without haematological problems. After 22 months of therapy, the intravenous immunoglobulin was discontinued; a durable remission was subsequently maintained. Intravenous immunoglobulin may be the treatment of choice for females of child-bearing potential.
Collapse
Affiliation(s)
- M J Mant
- Department of Medicine, University of Alberta, Edmonton, Canada
| |
Collapse
|
12
|
Gaur S, Kesarwala H, Gavai M, Gupta M, Whitley-Williams P, Frenkel LD. Clinical immunology and infectious diseases. Pediatr Clin North Am 1994; 41:745-82. [PMID: 7519341 DOI: 10.1016/s0031-3955(16)38807-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Without the application of immunology, understanding of the pathogenesis and pathophysiology of infectious diseases would be severely retarded. The development new vaccines for the prevention of infectious diseases has been based on new immunologic findings. Immunodiagnostic modalities have provided for the growth of diagnostic techniques for infectious diseases. Clinical immunology also has laid the groundwork for immunotherapies using the old intravenous immunoglobulin preparations and the new monoclonal antibodies, cytokines, and interferons.
Collapse
Affiliation(s)
- S Gaur
- Department of Pediatrics, UMDNJ-Robert Wood Johnson Medical School, New Brunswick
| | | | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- M Goldman
- Canadian Red Cross Society, Blood Services, Montreal, Quebec
| | | | | | | | | |
Collapse
|
14
|
Gao F, Prince AM, Pascual D, Horowitz B. Enhancement in the safety of immune globulins prepared from high-risk plasma. Vox Sang 1993; 64:204-9. [PMID: 8390765 DOI: 10.1111/j.1423-0410.1993.tb03056.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Hyperimmune gamma-globulins have proven efficacious in the prevention and treatment of viral infections, including those caused by hepatitis A and B viruses, cytomegalovirus, parvovirus. Interest in the prevention and/or treatment of infections caused by human immunodeficiency virus (HIV) has led to clinical trials with anti-HIV immune plasma and purified immune globulin prepared from donors who are actively infected with HIV. The handling and fractionation of this or other infectious plasma requires the construction and operation of virus containment facilities designed to protect fractionation employees and the immediate environment. This requirement would be reduced substantially by applying virucidal procedures prior to or during plasma pooling. We have shown that heating plasma at 56 degrees C for 1 h followed by treatment with 1% tri(n-butyl) phosphate (TNBP) and 1% Triton X-100 for 4 h at 30 degrees C resulted in the inactivation of > or = 10(12.1) tissue culture infectious doses (TCID50) of HIV. With this treatment, the recovery of IgG was 87 +/- 3%. Fractionation of treated plasma by cold ethanol precipitation proceeded normally, and overall recovery, purity, and potency against selected viral markers were unaffected. The additional treatment of plasma with 15 g/l Aerosil for 4 h at 45 degrees C removed 10(4.5) TCID50 of HIV but resulted in substantial IgG losses both prior to and following fractionation. We conclude that potentially infectious plasma can be treated at 56 degrees C for 1 h and by TNBP/Triton X-100 at 30 degrees C for 4 h prior to fractionation. These steps appear sufficient to assure safety and to permit routine fractionation of plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- F Gao
- New York Blood Center, NY 10021
| | | | | | | |
Collapse
|
15
|
|
16
|
Abstract
Intravenous immunoglobulin (IVIgG) has many potential applications in haematology both as antibody replacement therapy and as an immune-modulater in autoimmune disorders. Antibody replacement appears to be of value in the prophylaxis of infection in low-grade B-cell malignancies, in bone marrow transplant recipients and in children with AIDS, although optimal treatment strategies have not been assessed and determining which patients are likely to derive greatest benefit has been problematic. IVIgG appears to be effective in the prevention or amelioration of CMV-related pathology if given frequently and has also dramatically improved the survival of patients with established interstitial pneumonia when used in combination with ganciclovir. Intriguingly, IVIgG appears to moderate the severity of GVHD in adult transplant recipients. IVIgG has short term efficacy in most patients with ITP but, as long term remissions are uncommon, it has become necessary to be more selective in the use of IVIgG in this disorder. The response to IVIgG in other immune-mediated cytopenias is similar with generally transient improvement but also with occasional spectacular cures. The treatment of the acquired haemophilias with IVIgG has yielded in vivo and vitro evidence to support the idiotype-antiidiotype theory of IVIgG immune-modulation and has also demonstrated significant differences in the sensitivity of coagulation factor autoantibodies and alloantibodies to IVIgG therapy. IVIgG has several roles in pregnancy related disorders, including the management of both mother and fetus in ITP during pregnancy, the antenatal and postnatal management of platelet alloimmunisation and also in the management of severe rhesus isoimmunisation. IVIgG is safe and well tolerated. The expense of this therapy should be balanced against the likely gains and the overall costs of alternative approaches.
Collapse
Affiliation(s)
- A A Todd
- Edinburgh and SE Scotland Blood Transfusion Service, UK
| | | |
Collapse
|
17
|
Marzusch K, Schnaidt M, Dietl J, Wiest E, Hofstaetter C, Gölz R. High-dose immunoglobulin in the antenatal treatment of neonatal alloimmune thrombocytopenia: case report and review. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 1992; 99:260-2. [PMID: 1606126 DOI: 10.1111/j.1471-0528.1992.tb14511.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- K Marzusch
- Department of Obstetrics and Gynaecology, University of Tuebingen, FRG
| | | | | | | | | | | |
Collapse
|
18
|
Salama A, Mueller-Eckhardt C. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia. Transfus Med Rev 1992; 6:17-25. [PMID: 1551002 DOI: 10.1016/s0887-7963(92)70152-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- A Salama
- Department of Internal Medicine, Justus Liebig University Giessen, Germany
| | | |
Collapse
|
19
|
Abstract
Patients infected with the human immunodeficiency virus (HIV) may have an antibody deficiency and a deficiency of cellular immunity. Intravenous immunoglobulin (IVIG) preparations may benefit HIV-infected children and adults with recurrent bacterial infections at doses of 200 to 400 mg/kg every 2 to 4 weeks. In addition, IVIG (1 to 2 g/kg) is effective at raising platelet counts to hemostatic levels in HIV-infected patients with idiopathic thrombocytopenic purpura and life-threatening bleeding. Indirect evidence also suggests that IVIG may be effective in preventing Pneumocystis carinii pneumonia. Finally, recent studies suggest that specific anti-HIV antibody preparations may have a therapeutic role, either as immunoglobulin concentrates or as immunoadhesions and immunotoxins. However, further investigations are needed to exclude antibody enhancement of HIV infection by the Fc receptor or the complement receptor.
Collapse
Affiliation(s)
- P L Yap
- Edinburgh Blood Transfusion Service, Scotland, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
20
|
Hammarström L, Smith CI. New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections. Infection 1990; 18:314-24. [PMID: 2125980 DOI: 10.1007/bf01647018] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- L Hammarström
- Department of Clinical Immunology, NOVUM, Huddinge Hospital, Sweden
| | | |
Collapse
|